tiprankstipranks
Haemonetics reports Q2 adjusted EPS $1.12, consensus $1.07
The Fly

Haemonetics reports Q2 adjusted EPS $1.12, consensus $1.07

Reports Q2 revenue $345.51M, consensus $342.65M. Chris Simon, Haemonetics (HAE)’ CEO, stated: “Strong second-quarter performance reflects progress executing our long-range plan and responding to market trends. We have evolved our portfolio to attractive products with meaningful demand to drive growth and margin expansion. We are advancing our leading positions to accelerate profitable growth in the second half of our fiscal year and beyond.”

Don't Miss our Black Friday Offers:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App